Other Events. As previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (“ SEC ”) on August 18, 2026, BioMarin Pharmaceutical Inc., a Delaware corporation (“ BioMarin ”), entered into a Share Purchase Agreement (the “ Purchase Agreement ”) with (i) Alesta Therapeutics B.V., a Dutch private limited liability company ( besloten vennootschap met beperkte aansprakelijkheid ) (“ Alesta ”), (ii) each of the holders of shares of Alesta identified…

Entry into a Material Definitive Agreement. On August 30, 2026 (the “ Effective Date ”), BioMarin Pharmaceutical Inc. (“ BioMarin ”) entered into a binding term sheet (the “ Term Sheet ”) with Ascendis Pharma A/S (“ Ascendis ”) that sets forth the terms and conditions for a global settlement and license agreement (the “ Agreement ”) that resolves all pending proceedings relating to the BioMarin Patent Rights (as defined below). In accordance with the Term Sheet, BioMarin will grant to Ascendi…

Entry into a Material Definitive Agreement. On August 17, 2026, BioMarin Pharmaceutical Inc., a Delaware corporation (“ BioMarin ”), entered into a Share Purchase Agreement (the “ Purchase Agreement ”) with (i) Alesta Therapeutics B.V., a Dutch private limited liability company ( besloten vennootschap met beperkte aansprakelijkheid ) (the “ Company ” or “ Alesta ”), (ii) each of the holders of shares of Alesta identified on Schedule 1.1(a) to the Purchase Agreement, (iii) Anaheim SpinCo B.V.,…

Results of Operations and Financial Condition. On August 6, 2026, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its second quarter ended June 30, 2026. The Company’s press release issued on August 6, 2026 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…

The filing describes an amendment to the equity incentive plan, not a management change.

Results of Operations and Financial Condition. On May 4, 2026, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its first quarter ended March 31, 2026. The Company’s press release issued on May 4, 2026 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

Entry into a Material Definitive Agreement. The information set forth in

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On the Closing Date, in connection with the Merger, the Company entered into a Credit Agreement (the “ Credit Agreement ”), by and among the Company, as borrower, the lenders and issuing banks from time to time party thereto, and Citibank, N.A., as administrative agent and collateral agent (in such capacities, the “ Administrative Agent ” and the “ Collateral Agent ,” respectivel…

by reference. At the effective time of the Merger (the “ Effective Time ”), each share of common stock, par value $0.01 per share, of Amicus (“ Amicus Common Stock ”) issued and outstanding immediately prior to the Effective Time (other than certain excluded shares as described in the Merger Agreement) was automatically cancelled and converted into the right to receive $14.50 in cash, without interest thereon and subject to any applicable withholding of taxes. Pursuant to the Merger Agreement…

Other Events. As previously disclosed, on December 19, 2025, BioMarin Pharmaceutical Inc. (“ BioMarin ”) and Lynx Merger Sub 1, Inc., a wholly owned subsidiary of BioMarin (“ Merger Sub ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Amicus Therapeutics, Inc. (“ Amicus ”), providing for the merger of Merger Sub with and into Amicus (the “ Merger ”), with Amicus surviving the Merger as a wholly owned subsidiary of BioMarin. On April 23, 2026, the Ministry of Eco…

Results of Operations and Financial Condition. On February 23, 2026, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its fourth quarter ended December 31, 2025. The Company’s press release issued on February 23, 2026 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Excha…

Entry into a Material Definitive Agreement. On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the Unite…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information provided in

Regulation FD Disclosure. On January 29, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) entered into a purchase agreement (the Purchase Agreement) with Morgan Stanley & Co. LLC as representative of the several initial purchasers listed in Schedule I thereto (collectively, the Initial Purchasers), relating to the sale by BioMarin of $850 million of 5.500% senior unsecured notes due 2034 (the Notes) in a private placement to qualified institutional buyers pursuant to Rule 144A und…

Regulation FD Disclosure. Notes Offering On January 26, 2026, BioMarin issued a press release announcing its intention to offer, subject to market and other conditions, $850 million of senior unsecured notes due 2034 (the Notes) in a private placement (the Offering) to a limited number of persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. BioMarin also announced that, in connection with the pending acquisition (the Acquisition) of…

Results of Operations and Financial Condition. On January 26, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) announced that it estimates having generated approximately $3.2 billion in total revenues (unaudited) for the year ended December 31, 2025, including approximately $920 million in revenues (unaudited) for the year ended December 31, 2025 from sales of VOXZOGO ® , and that, as of December 31, 2025, it had approximately $2.1 billion in cash, cash equivalents and investments…

Results of Operations and Financial Condition. On January 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) presented a business update at the 44th Annual J.P. Morgan Healthcare Conference (the Presentation), during which BioMarin disclosed that based on preliminary results BioMarin estimates that it generated approximately $3.2 billion in total revenues (unaudited) for the year ended December 31, 2025, including approximately $920 million in revenues (unaudited) for the year e…

Entry into a Material Definitive Agreement. Agreement and Plan of Merger On December 19, 2025, BioMarin Pharmaceutical Inc., a Delaware corporation (“ BioMarin ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Amicus Therapeutics, Inc. (the “ Company ” or “ Amicus ”), and Lynx Merger Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of BioMarin (“ Merger Sub ”), providing for the merger of Merger Sub with and into Amicus (the “ Merger ”), with Amic…

Chief Accounting Officer — Rashmi Ramchandani: The filing announces the external hire of a new Chief Accounting Officer, while the existing CFO retains their position, indicating a role addition rather than a departure.

Results of Operations and Financial Condition. On October 27, 2025, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its third quarter ended September 30, 2025. The Company’s press release issued on October 27, 2025 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchang…

Results of Operations and Financial Condition. E stimated Third Quarter 2025 Acquired In-Process Research and Development (IPR&D) Charges In connection with its previously announced acquisition of Inozyme Pharma, Inc. on July 1, 2025, BioMarin Pharmaceutical Inc. (BioMarin) expects that its reported financial results calculated in accordance with U.S. generally accepted accounting principles (GAAP) and its Non-GAAP financial results for the third quarter of 2025 will include acquired IPR&D ch…

Chief Accounting Officer — Erin Burkhart: The Chief Accounting Officer is voluntarily resigning, which is a genuine departure of a senior officer, though the company has an interim plan and no disagreement is reported.

Results of Operations and Financial Condition. On August 4, 2025, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its second quarter ended June 30, 2025. The Company’s press release issued on August 4, 2025 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…

Director — Ian T. Clark: The filing discloses the appointment of a new independent director to the board, which is a routine governance event and not a departure of a senior executive.

The filing discloses the approval of an equity incentive plan amendment, which is a compensatory arrangement rather than a change in management personnel.